CNVVY (CNVVY) Stock Price & Analysis
CNVVY (CNVVY) fell 2.53% to USD 10.79 as of June 10, 2026 at 06:00 UTC, according to Nexqual real-time market data.
CNVVY last closed at USD 11.07; the session ranged USD 10.79–11 on volume of 3,104 shares. Market capitalization is $5.27B, with a 52-week range of USD 10.45–16.65 (PNK). Source: Nexqual, June 10, 2026 at 06:00 UTC.
Key Statistics (as of June 10, 2026 at 06:00 UTC)
| Price | USD 10.79 |
|---|---|
| Change | ▼ 2.53% (down) |
| Previous Close | USD 11.07 |
| Open | USD 11 |
| Day Range | USD 10.79 – 11 |
| 52-Week Range | USD 10.45 – 16.65 |
| Volume | 3,104 shares |
| Market Cap | $5.27B |
| Exchange | PNK |
Technical Analysis (CNVVY)
Nexqual's technical model rates CNVVY "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:00 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.79 (neutral) |
| vs SMA50 | Below (USD 11.56) |
| MACD | -0.24 (negative) |
Analyst Ratings (CNVVY)
Wall Street analysts rate CNVVY "None" based on 1 analysts, with a mean price target of USD 13.8 (range USD 13.8–13.8), per Nexqual as of June 10, 2026 at 06:00 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 13.8 |
| High Target | USD 13.8 |
| Low Target | USD 13.8 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CNVVY)
Source: Nexqual, June 10, 2026 at 06:00 UTC.
Financials & Fundamentals (CNVVY)
| Total Revenue | $2.44B |
|---|---|
| Revenue Growth (YoY) | +7.10% |
| Gross Margin | +56.25% |
| Operating Margin | +18.08% |
| Profit Margin | +7.17% |
| ROE | +10.91% |
| Debt / Equity | 100 |
| Current Ratio | 1.53 |
| Total Cash | $68.00M |
| Total Debt | $1.52B |
| Free Cash Flow | $241.50M |
Source: Nexqual, June 10, 2026 at 06:00 UTC.
Financial Health Score (CNVVY)
Nexqual rates CNVVY's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 06:00 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 56%, operating 18% |
| Balance Sheet | Mixed — $68M cash vs $1.52B debt |
| Cash Flow | Solid — FCF $242M, 10% margin |
| Efficiency | Mixed — ROE 11%, ROA 7.0% |
Ownership (CNVVY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.34% |
| Shares Outstanding | 488.61M |
| Float | 486.56M |
Source: Nexqual, June 10, 2026 at 06:00 UTC.
Leadership (CNVVY)
CNVVY is led by Jonathan Peter Mason (age 61), CEO & Director, per Nexqual as of June 10, 2026 at 06:00 UTC.
| CEO & Director | Jonathan Peter Mason (age 61) |
|---|---|
| Group Financial Controller, CFO & Director | Fiona Victoria Ryder (age 50) |
| President & COO of Infusion Care | Kjersti Grimsrud Biotechnology, M.Sc. (age 64) |
| EVP and Chief Strategy & Business Development Officer | Evelyn Douglas |
| President & COO of Ostomy Care | Bruno Pinheiro |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLPBY | Coloplast AS | USD 6.06 | ▲ 1% |
| GNGBY | Getinge AB | USD 20.29 | ▼ 0.05% |
| EKTAY | Elekta AB | USD 5.61 | ▼ 2.09% |
| ANSLY | Ansell Ltd. | USD 78.77 | ▲ 5.9% |
| SSMXY | Sysmex Corp. | USD 9.04 | ▼ 1.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:00 UTC. This page is informational and not investment advice.